As more innovative drugs emerge for various forms of neuromuscular disease, the Food and Drug Administration is under increasing pressure to approve the treatments. Patients are understandably clamoring for cures, and the increasing demands from families have prompted lawmakers to scrutinize agency initiatives. Signs of the growing pressure were evident two years ago in the ruckus over the FDA’s approval of a medicine for Duchenne muscular dystrophy. Meanwhile, these treatments are being launched at increasingly high price points. On the eve of a Muscular Dystrophy Association conference, we spoke briefly with Dr. Janet Woodcock, who heads the Center for New Drug Evaluation and Research at the FDA, about agency moves to hasten approvals. This is an edited version of the conversation…

Pharmalot: In your view, how far have we come recently?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy